A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT.
Telomere length is maintained by two known mechanisms, the activation of telomerase or alternative lengthening of telomeres (ALT). The molecular mechanisms regulating the ALT phenotype are poorly understood and it is unknown how the decision of which pathway to activate is made at the cellular level. We have shown earlier that active repression of telomerase gene expression by chromatin remodelling of the promoters is one mechanism of regulation; however, other genes and signalling networks are likely to be required to regulate telomerase and maintain the ALT phenotype. Using gene expression profiling, we have uncovered a signature of 1305 genes to distinguish telomerase-positive and ALT cell lines. By combining this with the gene expression profiles of liposarcoma tissue samples, we refined this signature to 297 genes. A network analysis of known interactions between genes within this signature revealed a regulatory signalling network consistent with a model of human telomerase reverse transcriptase (hTERT) repression in ALT cell lines and liposarcomas. This network expands on our existing knowledge of hTERT regulation and provides a platform to understand differential regulation of hTERT in different tumour types and normal tissues. We also show evidence to suggest a novel mesenchymal stem cell origin for ALT immortalization in cell lines and mesenchymal tissues.
Lafferty-Whyte
K
K
Centre for Oncology and Applied Pharmacology, University of Glasgow, Cancer Research UK Beatson Laboratories, Bearsden, Glasgow G61 1BD, UK.
Cairney
C J
CJ
Will
M B
MB
Serakinci
N
N
Daidone
M-G
MG
Zaffaroni
N
N
Bilsland
A
A
Keith
W N
WN
D045744:Cell Line, Tumor; D020869:Gene Expression Profiling; D006801:Humans; D008080:Liposarcoma / Q000235:genetics; D059630:Mesenchymal Stem Cells / Q000378:metabolism*; D016271:Proto-Oncogene Proteins c-myc / Q000032:analysis / Q000378:metabolism; D019098:Telomerase / Q000032:analysis / Q000378:metabolism*; D016615:Telomere
C489427:MYC protein, human; D016271:Proto-Oncogene Proteins c-myc; C509186:TERT protein, human; D019098:Telomerase
Cytotherapy. 2005;7(6):509-19
16306013
Oncogene. 1996 Jul 4;13(1):161-6
8700542
Leukemia. 2003 Jun;17(6):1146-9
12764382
Regen Med. 2006 Jan;1(1):125-31
17465827
Clin Cancer Res. 2005 Jan 1;11(1):217-25
15671549
Cancer Res. 1999 Sep 1;59(17):4175-9
10485449
Oncogene. 2007 Jul 12;26(32):4635-47
17297460
Cancer Res. 2006 Nov 15;66(22):10849-54
17108121
Oncogene. 2004 Jun 24;23(29):5095-8
15107831
Nat Med. 1997 Nov;3(11):1271-4
9359704
Cancer Res. 2003 Apr 15;63(8):1759-63
12702558
Biochimie. 2008 Jan;90(1):13-23
17854971
Neoplasia. 2005 Nov;7(11):967-76
16331882
Br J Cancer. 2008 Apr 22;98(8):1467-74
18414473
Cancer Res. 2005 Sep 1;65(17):7585-90
16140922
J Exp Clin Cancer Res. 2008 Aug 12;27:27
18694522
Cancer Res. 2006 Sep 1;66(17):8918-24
16951210
Cancer Res. 2005 Apr 15;65(8):3035-9
15833829
Stem Cells. 2006 Apr;24(4):1095-103
16282438
Cancer Cell. 2007 May;11(5):421-9
17482132
Biochim Biophys Acta. 2008 Feb;1783(2):193-202
17919748
Oncogene. 2002 Jan 21;21(4):598-610
11850785
Cancer Res. 2006 Jul 1;66(13):6473-6
16818615
Cancer Res. 2008 Apr 1;68(7):2176-85
18381423
J Biol Chem. 2007 Oct 5;282(40):29314-22
17693401
Genes Chromosomes Cancer. 2004 Oct;41(2):155-62
15287028
Clin Cancer Res. 2005 Aug 1;11(15):5347-55
16061847
Lancet. 2003 Mar 8;361(9360):836-8
12642053
Cancer Res. 2007 Oct 1;67(19):9142-9
17909019
J Clin Invest. 2007 Nov;117(11):3248-57
17948129
Biochem Biophys Res Commun. 2008 May 16;369(4):1114-9
18339310
Cancer Res. 2007 Sep 1;67(17):8216-22
17804735